Fmr LLC Buys 46,892 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

Fmr LLC boosted its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 25.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 227,981 shares of the biopharmaceutical company’s stock after buying an additional 46,892 shares during the quarter. Fmr LLC owned approximately 0.20% of Fate Therapeutics worth $798,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Intech Investment Management LLC bought a new position in shares of Fate Therapeutics during the third quarter worth about $108,000. Thrivent Financial for Lutherans raised its holdings in Fate Therapeutics by 24.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 125,370 shares of the biopharmaceutical company’s stock worth $439,000 after purchasing an additional 24,804 shares during the last quarter. Privium Fund Management B.V. bought a new position in Fate Therapeutics during the 3rd quarter worth approximately $175,000. Castleview Partners LLC acquired a new position in shares of Fate Therapeutics in the 3rd quarter worth approximately $73,000. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Fate Therapeutics by 40.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 42,289 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 12,230 shares during the last quarter. Institutional investors own 97.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Wedbush reiterated a “neutral” rating and set a $5.00 price target on shares of Fate Therapeutics in a report on Tuesday, November 12th. Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a report on Tuesday, November 19th. Bank of America raised Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday, November 18th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $6.75.

Fate Therapeutics Stock Down 6.0 %

NASDAQ FATE opened at $1.88 on Wednesday. Fate Therapeutics, Inc. has a 52 week low of $1.82 and a 52 week high of $8.83. The business has a 50 day moving average price of $2.63 and a 200-day moving average price of $3.38. The company has a market cap of $214.12 million, a price-to-earnings ratio of -1.14 and a beta of 1.95.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.02. The firm had revenue of $3.07 million for the quarter, compared to the consensus estimate of $0.88 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. On average, equities research analysts anticipate that Fate Therapeutics, Inc. will post -1.72 earnings per share for the current year.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.